Traditional liquid biopsies for brain cancer are limited by the blood-brain barrier, but new AI-driven methods are improving detection. Researchers at Johns Hopkins University developed a technique that analyzes DNA fragments from tumors and immune cells in the blood, achieving about 75% detection in early studies. Another system, crossNN, examines epigenetic signatures and can classify […]
On September 9, 2025, the U.S. Food and Drug Administration approved INLEXZO™ (gemcitabine intravesical system), developed by Janssen Biotech. It is the first device that continuously releases chemotherapy inside the bladder for cancer treatment. Instead of placing liquid chemotherapy in the bladder for one to two hours per visit, this small flexible tube stays in
FDA Approves INLEXZO™: First Extended-Release Bladder Cancer Treatment System Read More »
Ovarian cancer treatment is becoming more personalized and stage-specific, guided by tumor genetics. In early stages (I–II), minimally invasive and robotic surgeries reduce recovery time and pain. Fertility-sparing surgery allows some younger patients to preserve reproductive potential. Genomic profiling is also helping determine which patients truly need chemotherapy, avoiding unnecessary side effects. In advanced stages
New technologies are transforming early ovarian cancer detection, aiming to identify this “silent killer” at more treatable stages. AI-powered tools like Ovatools combine biomarkers such as CA125 with patient data to generate personalized risk scores, improving early diagnosis. Machine learning is also being used to analyze metabolic patterns in blood, detecting subtle cancer signals with
Revolutionary Technologies Transform Early Ovarian Cancer Detection Read More »
n September 9, 2025, the FDA approved INLEXZO™ (gemcitabine intravesical system) by Janssen Biotech. It is the first device that releases chemotherapy directly inside the bladder over time. Unlike traditional treatments where liquid chemo stays in the bladder for 1–2 hours, INLEXZO™ is a small tube that stays in the bladder and delivers the drug
Pancreatic Cancer Treatment Revolution: Breakthrough Therapies Target the “Untreatable” Read More »
New technologies are advancing early pancreatic cancer detection using highly sensitive blood tests and AI. Magnetic nanosensors can detect tumor-released proteases from just a small blood sample in under an hour at extremely low cost. When combined with CA 19-9, early-stage detection accuracy reaches about 85%. AI-powered DNA fragment analysis also shows strong results, with
Liquid biopsy is transforming lymphoma diagnosis and monitoring by analyzing circulating tumor DNA (ctDNA) from blood instead of traditional tissue biopsies. This approach enables early detection and helps track treatment response. For example, EBV DNA can be detected in T-cell lymphoma, and AI can enhance monitoring in follicular lymphoma, offering more precise insights into disease
From Blood to Bytes: Modern Diagnostic Advances in Lymphoma Read More »
A new report from cancer research organizations highlights that 40% of all U.S. cancers are linked to modifiable risk factors, emphasizing prevention as a key strategy. Tobacco remains the largest contributor, causing nearly 20% of cancers and 17 different cancer types. Even e-cigarettes carry risks, increasing the likelihood of switching to traditional smoking. Maintaining a
Seven Key Lifestyle Changes That Can Prevent 40% of All Cancers Read More »
New research from Edith Cowan University shows that just one session of resistance training or high-intensity interval training can significantly benefit cancer survivors. The study fund that a single workout increases myokines—muscle-produced proteins with anti-cancer properties—which can reduce cancer cell growth by 20-30%. The study measured myokine levels in breast cancer survivors before, immediately after, and
Single Exercise Session Boosts Anti-Cancer Proteins in Breast Cancer Survivors Read More »
New genetic markers have been developed by researchers in the UK and Spain to predict how well a person’s cancer will respond to certain types of chemotherapy. These markers, called CIN signatures, measure chromosomal instability in a tumor and can tell doctors if a patient is likely to be resistant to specific drugs. The biomarkers were
Breakthrough CIN Biomarkers: Predicting Chemotherapy Resistance Read More »